Natural killer cells: Versatile roles in autoimmune and infectious diseases

Expert Review of Clinical Immunology

Volumn 5, Issue 4, 2009, Pages 405-420

  Aktas, Esin ^a   Erten, Gaye ^a   Kucuksezer, Umut Can ^a   Deniz, Gunnur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Autoimmunity; Cytokines; Cytotoxic activity; Infectious diseases; NK cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; MAJOR HISTOCOMPATIBILITY ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BEHCET DISEASE; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DENDRITIC CELL; DISEASE COURSE; HEPATITIS C; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER T CELL; NONHUMAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS;

EID: 77649168118     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.27     Document Type: Review

References (181)

1. Trinchieri G. Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin. Immunol. 7(2), 83-88 (1995).
2. Caligiuri MA. Human natural killer cells. Blood 112(3), 461-469 (2008).
3. Colonna M. NK cells: new issues and challenges. Eur. J. Immunol. 38(11), 2927-2929 (2008).
4. Shibuya A, Kojima H, Shibuya K, Nagayoshi K, Nagasawa T, Nakauchi H. Enrichment of interleukin-2-responsive natural killer progenitors in human bone marrow. Blood 81(7), 1819-1826 (1993).
5. Shereck E, Satwani P, Morris E, Cairo MS. Human natural killer cells in health and disease. Pediatr. Blood Cancer 49(5), 615-623 (2007).
6. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87(7), 2632-2640 (1996).
7. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191(5), 771-780 (2000).
8. Di Santo JP. Functionally distinct NK-cell subsets: developmental origins and biological implications. Eur. J. Immunol. 38(11), 2948-2951 (2008).
9. Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1βcostimulates interferon-γproduction by human natural killer cells. Eur. J. Immunol. 31(3), 792-801 (2001).
10. Kunikata T, Torigoe K, Ushio S et al. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell. Immunol. 189(2), 135-143 (1998).
11. Carson WE, Lindemann MJ, Baiocchi R et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 85(12), 3577-3585 (1995).
12. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162(8), 4511-4520 (1999).
13. Maki G, Krystal G, Dougherty G, Takei F, Klingemann HG. Induction of sensitivity to NK-mediated cytotoxicity by TNF-α treatment: possible role of ICAM-3 and CD44. Leukemia 12(10), 1565-1572 (1998).
14. Bennett M, Taylor PA, Austin M et al. Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: influence of mouse colony environment. Int. Immunol. 10(6), 785-790 (1998).
15. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-γproduction by IL-12 and IL-18. Curr. Opin. Immunol. 10(3), 259-264 (1998).
16. Gosselin J, TomoIu A, Gallo RC, Flamand L. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 94(12), 4210-4219 (1999).
17. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169(5), 1747-1756 (1989).
18. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6), 673-682 (1995).
19. Gismondi A, Cifaldi L, Mazza C et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 104(2), 436-443 (2004).
20. Cooper MA, Caligiuri MA. Isolation and characterization of human natural killer cell subsets. Curr. Protoc. Immunol. Chapter 7, Unit 7, 34 (2004).
21. Kern WF, Spier CM, Miller TP, Grogan TM. NCAM (CD56)-positive malignant lymphoma. Leuk. Lymphoma 12(1-2), 1-10 (1993).
22. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIIIpositive and negative natural killer cells. J. Immunol. 143(10), 3183-3191 (1989).
23. Robertson MJ, Soiffer RJ, Wolf SF et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175(3), 779-788 (1992).
24. Konjevic G, Schlesinger B, Cheng L, Olsen KJ, Podack ER, Spuzic I. Analysis of perforin expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2. Immunol. Invest. 24(3), 499-507 (1995).
25. Berahovich RD, Lai NL, Wei Z, Lanier LL, Schall TJ. Evidence for NK cell subsets based on chemokine receptor expression. J. Immunol. 177(11), 7833-7840 (2006).
26. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161(11), 5821-5824 (1998).
27. Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets determined by purification of IFN-γsecreting and IFN-γ-nonsecreting NK cells. Eur. J. Immunol. 32(3), 879-884 (2002).
28. Giuliani M, Giron-Michel J, Negrini S et al. Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS ONE 3(5), e2241 (2008).
29. Deniz G, Erten G, Kucuksezer UC et al. Regulatory NK cells suppress antigenspecific T cell responses. J. Immunol. 180(2), 850-857 (2008).
30. Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457(7230), 722-725 (2009).
31. Rolstad B, Herberman RB, Reynolds CW. Natural killer cell activity in the rat. V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL). J. Immunol. 136(8), 2800-2808 (1986).
32. Biron CA, Turgiss LR, Welsh RM. Increase in NK cell number and turnover rate during acute viral infection. J. Immunol. 131(3), 1539-1545 (1983).
33. Taniguchi K, Petersson M, Hoglund P, Kiessling R, Klein G, Karre K. Interferonγ induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc. Natl Acad. Sci. USA 84(10), 3405-3409 (1987).
34. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101(8), 3052-3057 (2003).
35. Ferlazzo G, Thomas D, Lin SL et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172(3), 1455-1462 (2004).
36. Frey M, Packianathan NB, Fehniger TA et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J. Immunol. 161(1), 400-408 (1998).
37. Robertson MJ. Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 71(2), 173-183 (2002).
38. Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA 101(47), 16606-16611 (2004).
39. Cooper MA, Fehniger TA, Turner SC et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97(10), 3146-3151 (2001).
40. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195(3), 327-333 (2002).
41. Carnaud C, Lee D, Donnars O et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163(9), 4647-4650 (1999).
42. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195(3), 343-351 (2002).
43. Schott E, Bonasio R, Ploegh HL. Elimination in vivo of developing T cells by natural killer cells. J. Exp. Med. 198(8), 1213-1224 (2003).
44. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195(3), 335-341 (2002).
45. Della Chiesa M, Sivori S, Castriconi R, Marcenaro E, Moretta A. Pathogeninduced private conversations between natural killer and dendritic cells. Trends Microbiol. 13(3), 128-136 (2005). (Pubitemid 40311895)
46. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100(6), 1935-1947 (2002).
47. Ljunggren HG, Karre K. In search of the 'missing self ': MHC molecules and NK cell recognition. Immunol. Today 11(7), 237-244 (1990).
48. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killercell self-tolerance. Nat. Rev. 5(5), 363-374 (2005).
49. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cellmediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001).
50. Gardiner CM. Killer cell immunoglobulinlike receptors on NK cells: the how, where and why. Int. J. Immunogenet. 35(1), 1-8 (2008).
51. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin. Exp. Immunol. 149(1), 1-8 (2007).
52. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl. Immunol. 10(2-3), 147-164 (2002).
53. Long EO, Barber DF, Burshtyn DN et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol. Rev. 181, 223-233 (2001).
54. Huard B, Karlsson L. A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur. J. Immunol. 30(6), 1665-1675 (2000).
55. Plougastel B, Jones T, Trowsdale J. Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene. Immunogenetics 44(4), 286-291 (1996).
56. Glienke J, Sobanov Y, Brostjan C et al. The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics 48(3), 163-173 (1998).
57. Phillips JH, Chang C, Mattson J, Gumperz JE, Parham P, Lanier LL. CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA-A, HLA-B, and HLA-C allotypes. Immunity 5(2), 163-172 (1996).
58. Sivori S, Vitale M, Morelli L et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J. Exp. Med. 186(7), 1129-1136 (1997).
59. Vitale M, Bottino C, Sivori S et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187(12), 2065-2072 (1998).
60. Mandelboim O, Porgador A. NKp46. Int. J. Biochem. Cell Biol. 33(12), 1147-1150 (2001).
61. Andre I, Gonzalez A, Wang B, Katz J, Benoist C, Mathis D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl Acad. Sci. USA 93(6), 2260-2263 (1996).
62. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol. 81, 331-371 (2003).
63. Shi FD, Ljunggren HG, Sarvetnick N. Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol. 22(2), 97-101 (2001).
64. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res. Ther. 6(1), 8-14 (2004).
65. Johansson S, Berg L, Hall H, Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol. 26(11), 613-618 (2005).
66. Momot T, Koch S, Hunzelmann N et al. Association of killer cell immunoglobulinlike receptors with scleroderma. Arthritis Rheum. 50(5), 1561-1565 (2004).
67. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. 3(10), 781-790 (2003).
68. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 127(Pt 9), 1917-1927 (2004).
69. Takahashi K, Miyake S, Kondo T et al. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Invest. 107(5), R23-R29 (2001).
70. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 186(10), 1677-1687 (1997).
71. Matsumoto Y, Kohyama K, Aikawa Y et al. Role of natural killer cells and TCR T cells in acute autoimmune encephalomyelitis. Eur. J. Immunol. 28(5), 1681-1688 (1998).
72. Shi FD, Takeda K, Akira S, Sarvetnick N, Ljunggren HG. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-γδby NK cells. J. Immunol. 165(6), 3099-3104 (2000).
73. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174(5), 2696-2701 (2005).
74. Backstrom E, Chambers BJ, Kristensson K, Ljunggren HG. Direct NK cell-mediated lysis of syngenic dorsal root ganglia neurons in vitro. J. Immunol. 165(9), 4895-4900 (2000).
75. Morse RH, Seguin R, McCrea EL, Antel JP. NK cell-mediated lysis of autologous human oligodendrocytes. J. Neuroimmunol. 116(1), 107-115 (2001).
76. Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. Lymphocyte subsets in a large cohort of patients with systemic lupus erythematosus. Lupus 2(4), 227-231 (1993).
77. Sibbitt WL Jr, Mathews PM, Bankhurst AD. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers. J. Clin. Invest. 71(5), 1230-1239 (1983).
78. Schepis D, Gunnarsson I, Eloranta ML et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 126(1), 140-146 (2008).
79. Perricone R, Perricone C, De Carolis C, Shoenfeld Y. NK cells in autoimmunity: a two-edg'd weapon of the immune system. Autoimmun Rev. 7(5), 384-390 (2008).
80. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356(6367), 314-317 (1992).
81. Yabuhara A, Yang FC, Nakazawa T et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J. Rheumatol. 23(1), 171-177 (1996).
82. Shi FD, Wang HB, Li H et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1(3), 245-251 (2000).
83. Vranes Z, Poljakovic Z, Marusic M. Natural killer cell number and activity in multiple sclerosis. J. Neurol. Sci. 94(1-3), 115-123 (1989).
84. Liu R, Van Kaer L, La Cava A et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol. 176(9), 5247-5254 (2006).
85. Martin MP, Nelson G, Lee JH et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J. Immunol. 169(6), 2818-2822 (2002).
86. Nelson GW, Martin MP, Gladman D, Wade J, Trowsdale J, Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173(7), 4273-4276 (2004).
87. Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 52(11), 3586-3595 (2005).
88. Silver RM. Studies of rheumatoid synovial fluid lymphocytes. III. Phenotypic and functional analysis of natural killer-like cells. Clin. Immunol. Immunopathol. 39(1), 159-167 (1986).
89. Pridgeon C, Lennon GP, Pazmany L, Thompson RN, Christmas SE, Moots RJ. Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit a CD56bright, CD94bright, CD158negative phenotype. Rheumatology (Oxford) 42(7), 870-878 (2003).
90. Mingari MC, Vitale C, Cantoni C et al. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. Eur. J. Immunol. 27(6), 1374-1380 (1997).
91. McInnes IB, al-Mughales J, Field M et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat. Med. 2(2), 175-182 (1996).
92. Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J. Rheumatol. 29(5), 1111-1114 (2002).
93. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 42(2), 375-379 (2003).
94. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemiconset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142(3), 292-296 (2003).
95. Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin. Exp. Immunol. 71(1), 126-131 (1988).
96. Kaneko F, Takahashi Y, Muramatsu R et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behcet's disease. Br. J. Dermatol. 113(3), 313-318 (1985).
97. Onder M, Bozkurt M, Gurer MA, Gulekon A, Sezgin P, Imir T. Natural cellular cytotoxicity in Behcet's disease. J. Dermatol. 21(4), 239-243 (1994).
98. Voorter CE, van der Vlies S, Kik M, van den Berg-Loonen EM. Unexpected Bw4 and Bw6 reactivity patterns in new alleles. Tissue antigen 56(4), 363-370 (2000).
99. Saruhan-Direskeneli G, Uyar FA, Cefle A et al. Expression of KIR and C-type lectin receptors in Behcet's disease. Rheumatology (Oxford) 43(4), 423-427 (2004).
100. Mizuki N, Inoko H, Ando H et al. Behcet's disease associated with one of the HLA-B51 subantigens, HLA-B* 5101. Am. J. Ophthalmol. 116(4), 406-409 (1993).
101. Boitard C. The origin of Type 1 diabetes: an autoimmune disease? Diabetes Metab. 28(4 Pt 1), 263-265 (2002).
102. Baxter AG, Smyth MJ. The role of NK cells in autoimmune disease. Autoimmunity 35(1), 1-14 (2002).
103. Dotta F, Censini S, van Halteren AG et al. Coxsackie B4 virus infection ofβcells and natural killer cell insulitis in recent-onset Type 1 diabetic patients. Proc. Natl Acad. Sci. USA 104(12), 5115-5120 (2007).
104. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc. Natl Acad. Sci. USA 101(21), 8102-8107 (2004).
105. Alba A, Planas R, Clemente X et al. Natural killer cells are required for accelerated Type 1 diabetes driven by interferon-β. Clin. Exp. Immunol. 151(3), 467-475 (2008).
106. Negishi K, Waldeck N, Chandy G et al. Natural killer cell and islet killer cell activities in type 1 (insulin-dependent) diabetes. Diabetologia 29(6), 352-357 (1986).
107. Lorini R, Moretta A, Valtorta A et al. Cytotoxic activity in children with insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 23(1), 37-42 (1994). (Pubitemid 24118513)
108. Fidan I, Yuksel S, Kalkanci A, Imir T, Kustimur S. Evaluation of the natural killer cytotoxicity and the levels of cytokines in rats with Type I diabetes mellitus. Mem. Inst. Oswaldo Cruz 100(8), 883-887 (2005).
109. Rodacki M, Svoren B, Butty V et al. Altered natural killer cells in Type 1 diabetic patients. Diabetes 56(1), 177-185 (2007).
110. van der Slik AR, Koeleman BP, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in Type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52(10), 2639-2642 (2003).
111. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18(4), 391-398 (2006).
112. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. 5(11), 835-843 (2005).
113. Ward J, Barker E. Role of natural killer cells in HIV pathogenesis. Curr. HIV/AIDS Rep. 5(1), 44-50 (2008).
114. Kassim SH, Rajasagi NK, Ritz BW et al. Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1 (HSV-1). J. Virol. 83(7), 3175-3186 (2009).
115. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31(4), 429-434 (2002).
116. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr. HIV Res. 6(5), 433-440 (2008).
117. Tarazona R, Casado JG, Delarosa O et al. Selective depletion of CD56dim NK cell subsets and maintenance of CD56bright NK cells in treatment-naive HIV-1-seropositive individuals. J. Clin. Immunol. 22(3), 176-183 (2002).
118. Scott-Algara D, Paul P. NK cells and HIV infection: lessons from other viruses. Curr. Mol. Med. 2(8), 757-768 (2002).
119. Scott-Algara D, Truong LX, Versmisse P et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171(11), 5663-5667 (2003).
120. Rook AH, Masur H, Lane HC et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J. Clin. Invest. 72(1), 398-403 (1983).
121. Ratcliffe LT, Lukey PT, MacKenzie CR, Ress SR. Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis. Clin. Exp. Immunol. 97(3), 373-379 (1994).
122. Ahmad A, Menezes J. Positive correlation between the natural killer and gp 120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10(2), 115-119 (1995).
123. Lanier LL. NK cell receptors. Annu. Rev. Immunol. 16, 359-393 (1998).
124. Salter RD, Parham P. Mutually exclusive public epitopes of HLA-A,B,C molecules. Hum. Immunol. 26(2), 85-89 (1989).
125. Flores-Villanueva PO, Yunis EJ, Delgado JC et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl Acad. Sci. USA 98(9), 5140-5145 (2001).
126. den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27? AIDS Rev. 6(2), 89-96 (2004).
127. Mavilio D, Benjamin J, Daucher M et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl Acad. Sci. USA 100(25), 15011-15016 (2003).
128. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551 (2003).
129. Gao X, Nelson GW, Karacki P et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344(22), 1668-1675 (2001).
130. Qi Y, Martin MP, Gao X et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2(8), e79 (2006).
131. Boulet S, Kleyman M, Kim JY et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS (London, England) 22(12), 1487-1491 (2008).
132. Fehniger TA, Herbein G, Yu H et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J. Immunol. 161(11), 6433-6438 (1998).
133. Oliva A, Kinter AL, Vaccarezza M et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102(1), 223-231 (1998).
134. Jiang Y, Zhang Z, Diao Y et al. Expression of chemokine receptors on natural killer cells in HIV-infected individuals. Cell. Immunol. 251(1), 19-24 (2008).
135. Kottilil S, Chun TW, Moir S et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187(7), 1038-1045 (2003).
136. Chehimi J, Marshall JD, Salvucci O et al. IL-15 enhances immune functions during HIV infection. J. Immunol. 158(12), 5978-5987 (1997).
137. d'Ettorre G, Andreotti M, Carnevalini M et al. Interleukin-15 enhances the secretion of IFN-γδand CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunol. Lett. 103(2), 192-195 (2006).
138. Strbo N, de Armas L, Liu H, Kolber MA, Lichtenheld M, Pahwa S. IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS (London, England) 22(13), 1551-1560 (2008).
139. Rodriguez AR, Arulanandam BP, Hodara VL et al. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. J. Gen. Virol. 88(Pt 2), 641-651 (2007).
140. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320(26), 1731-1735 (1989).
141. Scalzo AA. Successful control of viruses by NK cells - a balance of opposing forces? Trends Microbiol. 10(10), 470-474 (2002).
142. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (New York, NY ) 296(5571), 1323-1326 (2002).
143. Smith HR, Heusel JW, Mehta IK et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl Acad. Sci. USA 99(13), 8826-8831 (2002).
144. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr. Opin. Immunol. 17(1), 29-35 (2005).
145. Andoniou CE, van Dommelen SL, Voigt V et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6(10), 1011-1019 (2005).
146. French AR, Sjolin H, Kim S et al. DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J. Immunol. 177(8), 4981-4990 (2006).
147. Rolle A, Mousavi-Jazi M, Eriksson M et al. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: upregulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J. Immunol. 171(2), 902-908 (2003).
148. Lopez-Botet M, Angulo A, Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue antigen 63(3), 195-203 (2004).
149. Tomasec P, Wang EC, Davison AJ et al. Downregulation of natural killer cellactivating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol. 6(2), 181-188 (2005).
150. Guma M, Angulo A, Vilches C, Gomez- Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 104(12), 3664-3671 (2004).
151. Zaia JA, Sun JY, Gallez-Hawkins GM et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol. Blood Marrow Transplant 15(3), 315-325 (2009).
152. Thomson M, Nascimbeni M, Havert MB et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J. Virol. 77(2), 862-870 (2003).
153. Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J. Leukoc. Biol. 76(4), 743-759 (2004).
154. Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645-1655 (2003).
155. Wang SH, Huang CX, Ye L et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J. Viral. Hepat. 15(12), 855-864 (2008).
156. Fukuda R, Ishimura N, Kushiyama Y et al. Effectiveness of interferon-γtherapy in chronic hepatitis C is associated with the amount of interferon-γreceptor mRNA in the liver. J. Hepatol. 26(3), 455-461 (1997).
157. Larkin J, Bost A, Glass JI, Tan SL. Cytokine-activated natural killer cells exert direct killing of hepatoma cells harboring hepatitis C virus replicons. J. Interferon Cytokine Res. 26(12), 854-865 (2006).
158. Jinushi M, Takehara T, Tatsumi T et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer 104(3), 354-361 (2003).
159. Bertone S, Schiavetti F, Bellomo R et al. Transforming growth factor-β-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. Eur. J. Immunol. 29(1), 23-29 (1999).
160. Nelson DR, Gonzalez-Peralta RP, Qian K et al. Transforming growth factor-β?1 in chronic hepatitis C. J. Viral Hepat. 4(1), 29-35 (1997).
161. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (New York, NY) 305(5685), 872-874 (2004).
162. Lopez-Vazquez A, Rodrigo L, Martinez- Borra J et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis. 192(1), 162-165 (2005).
163. Crotta S, Stilla A, Wack A et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195(1), 35-41 (2002).
164. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195(1), 43-49 (2002).
165. Meier UC, Owen RE, Taylor E et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79(19), 12365-12374 (2005).
166. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 10(9), 995-1004 (2008).
167. Junqueira-Kipnis AP, Kipnis A, Jamieson A et al. NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J. Immunol. 171(11), 6039-6045 (2003).
168. Stenger S, Rosat JP, Bloom BR, Krensky AM, Modlin RL. Granulysin: a lethal weapon of cytolytic T cells. Immunol. Today 20(9), 390-394 (1999).
169. Sahiratmadja E, Alisjahbana B, Buccheri S et al. Plasma granulysin levels and cellular interferon-γproduction correlate with curative host responses in tuberculosis, while plasma interferon-γlevels correlate with tuberculosis disease activity in adults. Tuberculosis (Edinburgh, Scotland) 87(4), 312-321 (2007).
170. Denis M. Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cell. Immunol. 156(2), 529-536 (1994).
171. Ramana Rao PV, Rajasekaran S, Raja A. Augumentation of natural killer activity with exogenous interleukins in patients with HIV and pulmonary tuberculosis coinfection. AIDS Res. Hum. Retroviruses 24(11), 1435-1443 (2008).
172. Umemura M, Nishimura H, Hirose K, Matsuguchi T, Yoshikai Y. Overexpression of IL-15 in vivo enhances protection against Mycobacterium bovis bacillus Calmette- Guerin infection via augmentation of NK and T cytotoxic 1 responses. J. Immunol. 167(2), 946-956 (2001).
173. Vankayalapati R, Wizel B, Weis SE et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 168(7), 3451-3457 (2002).
174. Vankayalapati R, Garg A, Porgador A et al. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 175(7), 4611-4617 (2005).
175. Millman AC, Salman M, Dayaram YK, Connell ND, Venketaraman V. Natural killer cells, glutathione, cytokines, and innate immunity against Mycobacterium tuberculosis. J. Interferon Cytokine Res. 28(3), 153-165 (2008).
176. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188(12), 2375-2380 (1998).
177. Brill KJ, Li Q, Larkin R et al. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via
178. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 180(3), 1729-1736 (2008).
179. Schierloh P, Aleman M, Yokobori N et al. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation. Immunology 116(4), 541-552 (2005).
180. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 20(3), 123-137 (2006).
181. Deniz G, Erten G, Kücüksezer UC et al. Regulatory NK cells suppress antigenspecific T cell responses. J. Immunol. 180(2), 850-857 (2008).